Company intelligence / Profile preview

Art of the Storm

Cambridge, England, United Kingdomspirituallifefoundation.org ↗

Ownership: Private
Development stage: Other

Overview

STC‑15, a first-in-class small molecule METTL3 inhibitor, has shown durable clinical activity and tolerability in Phase 1 studies with tumor regressions at all dose levels. The overall response rate was 9% with a disease control rate of 67%. The company is advancing to combination studies with checkpoint inhibitors such as LOQTORZI® (toripalimab) in multiple solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Coherus BioSciences (clinical collaboration on LOQTORZI®/toripalimab)Evotec SE (drug discovery collaboration/platform support)

Beyond the preview

Go deeper on Art of the Storm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Art of the Storm.

Explore the full profile